Luder PJ, Siffert B, Witassek F, Meister F, Bircher J; Siffert; Witassek; Meister; Bircher (1986). “Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions”. European journal of clinical pharmacology31 (4): 443–448. doi:10.1007/bf00613522. PMID3816925.
Martarelli D, Pompei P, Baldi C, Mazzoni G (April 2008). “Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice”. Cancer Chemother. Pharmacol.61 (5): 809–17. doi:10.1007/s00280-007-0538-0. PMID17581752.
Doudican N, Rodriguez A, Osman I, Orlow SJ (August 2008). “Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells”. Mol. Cancer Res.6 (8): 1308–15. doi:10.1158/1541-7786.MCR-07-2159. PMID18667591.
drugs.com
“Mebendazole”. The American Society of Health-System Pharmacists. Aug 18, 2015閲覧。
Luder PJ, Siffert B, Witassek F, Meister F, Bircher J; Siffert; Witassek; Meister; Bircher (1986). “Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions”. European journal of clinical pharmacology31 (4): 443–448. doi:10.1007/bf00613522. PMID3816925.
Martarelli D, Pompei P, Baldi C, Mazzoni G (April 2008). “Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice”. Cancer Chemother. Pharmacol.61 (5): 809–17. doi:10.1007/s00280-007-0538-0. PMID17581752.
Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T (November 2002). “The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells”. Mol. Cancer Ther.1 (13): 1201–9. PMID12479701.
Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA (September 2002). “Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo”. Clin. Cancer Res.8 (9): 2963–9. PMID12231542.
Doudican N, Rodriguez A, Osman I, Orlow SJ (August 2008). “Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells”. Mol. Cancer Res.6 (8): 1308–15. doi:10.1158/1541-7786.MCR-07-2159. PMID18667591.